PTEN/TMPRSS2:ERG: Clinical Validation

Kaplan-Meier and multivariate analysis indicate that TMPRSS2:ERG fusion and PTEN loss together are a predictor of earlier biochemical recurrence of disease.


Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

Modern Pathology, Yoshimoto et al. 2008 Dec;21(12):1451-60. doi: 10.1038/modpathol.2008.96.

              About PTEN/ERG
              The PTEN/ERG Report

              How to Order              
              Billing Information
              Useful Resources